NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 9 May 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Michael Chambers Present for all items
4. Dawn Cooper Present for all items
5. Dr Mark Corbett Present for all items
6. Dr Prithwiraj Das Present for all items
7. Dr David Foreman Present for all items
8. Dr Rob Forsyth Present for all items
9. Dr Pedro Saramago Goncalves Present for all items
10. John Hampson Present for all items
11. Louise Hunt Items 5.1.1 to 5.2.2
12. Dr Steven Lloyd Present for all items
13. Iain McGowan Present for all items
14. Ugochi Nwulu Items 1.1 to 4.1.3
15. Stella O’Brien Present for all items
16. Dr Clare Offer  Present for all items
17. Amit Parekh Present for all items
18. Dr Kate Ren Items 1.1 to 4.2.2
19. Professor Andrew Renehan Present for all items
20. Elizabeth Thurgar Present for all items
21. Dr Satish Venkateshan Present for all items

NICE staff (key players) present

Jasdeep Hayre, Associate Director Items 1.1 to 4.2.2

Celia Mayers, Project Manager Items 1.1 to 4.2.2

Alexandra Filby, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Dilan Savani, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 5.1.1 to 5.2.2

Louise Jafferally, Project Manager Items 5.1.1 to 5.2.2

Michelle Green, Heath Technology Assessment Adviser Items 5.1.1 to 5.2.2

Sharlene Ting, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

External assessment group representatives present

Daniel Gallacher, Warwick Evidence Items 1.1 to 4.1.3

Mary Jordan, Warwick Evidence Items 1.1 to 4.1.3

Tomos Robinson, Newcastle University Items 5.1.1 to 5.1.3

Dr Katie Thomson, Newcastle University Items 5.1.1 to 5.1.3

Clinical, Patient & NHS England experts present

Kate Monan, patient expert, nominated by PNH Support Items 1.1 to 4.1.3

Maria Piggin, Chair of PNH Support, patient expert, nominated by PNH Support

Items 1.1 to 4.1.3

Dr Talha Munir, Consultant Haematologist, clinical expert, nominated by Alexion Items 1.1 to 4.1.3

Dr Richard Kelly, Consultant Haematologist, clinical expert, nominated by the National PNH Service Items 1.1 to 4.1.3

Fiona Marley, Head of Highly Specialised Commissioning, commissioning expert, nominated by NHS England Items 1.1 to 4.1.3

Professor Peter Clark, CDF Lead, NHS England Items 5.1.1 to 5.1.3

Frank Burroughs, patient expert, nominated by Lymphoma Action

Items 5.1.1 to 5.1.3

Dr Kim Linton, Senior Lecturer and Honorary Consultant, clinical expert, nominated by BeiGene Items 5.1.1 to 5.1.3

Dr Renata Walewska, Consultant haematologist, clinical expert, nominated by the British Society for Haematology Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Professor Stephen O’Brien, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Dr Alex Cale, Dr Arpit Srivastava, and Iftab Akram.

### News and announcements

* 1. The Chair welcomed new committee member Louise Hunt who observed for her first meeting.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 3 April 2024

### Appraisal of danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public, and company representatives from Alexion Pharmaceuticals
     2. The Chair asked all committee members and experts, external assessment group representatives, and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10980).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Ugochi Nwulu, John Hampson, and Dr Pedro Saramago Goncalves.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10980>

### Appraisal of Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]

* 1. Part 1 – Open session
     1. The Chair, Professor Stephen O’Brien, welcomed the invited experts, external assessment group representatives, members of the public, and company representatives from BeiGene.
     2. The Chair asked all committee members and experts, external assessment group representatives, and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10962).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the Chair, Professor Andrew Renehan, and Elizabeth Thurgar.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10962>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 4 June 2024 and will start promptly at 09:00am.